New CAR-T therapy targets tough myeloma cases
NCT ID NCT07195617
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 27 times
Summary
This early study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The main goal is to check safety and see if it shrinks tumors. Only 10 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.